Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Ferring Pharmaceuticals Ltd
Drayton Hall, Church Road, West Drayton, UB7 7PS, UK
Telephone: +44 (0)844 931 0050
Fax: +44 (0)844 931 0051
WWW: http://www.ferring.co.uk
Medical Information Direct Line: +44 (0)844 931 0054
Medical Information e-mail: medical@ferring.com
Medical Information Fax: +44 (0)844 931 0051

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 21/03/2005
SPC Tractocile 7.5 mg/ml Concentrate for Solution for Infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 21/03/2005 and displayed until Current
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 3 - pharmaceutical form
  • Change to section 4.1 - Therapeutic Indications
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5 - Pharmacological Properties
  • Change to section 6.1 - List of Excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 9 - Date of Renewal of Authorisation
  • Change to section 10 (date of (partial) revision of the text
Updated on 22/09/2004 and displayed until 21/03/2005
Reasons for adding or updating:
  • Addition of Legal Category
Updated on 02/07/2004 and displayed until 22/09/2004
Reasons for adding or updating:
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 5.3 - Preclinical Safety Data
Updated on 10/06/2004 and displayed until 02/07/2004
Reasons for adding or updating:
  • Removal of Black Triangle
Updated on 11/03/2003 and displayed until 10/06/2004
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 28/08/2002 and displayed until 11/03/2003
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 22/08/2002 and displayed until 28/08/2002
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 17/08/2001 and displayed until 22/08/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 22/03/2001 and displayed until 17/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/02/2001 and displayed until 22/03/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  atosiban